METASTATIC BREAST CANCER

This early-phase study tested a new combination of drugs for people with a specific type of advanced breast cancer (HER2-positive with a PIK3CA mutation). The goal was to find the safest dose of the new drug (ipatasertib) when added to two standard treatments. Only 17 people took…

This early-phase study tested whether giving a type of focused radiation (stereotactic radiosurgery) after the immunotherapy drug nivolumab is safe and effective for people with breast cancer that has spread to the brain. Fourteen participants were enrolled to check for serious s…

This early-phase trial tested a combination of three drugs (olaparib, palbociclib, and fulvestrant) in 9 adults with BRCA-mutated, hormone receptor-positive, HER2-negative breast cancer that had spread or could not be removed. The main goal was to see if the combination was safe …

This study looked at whether adding focused radiation to the usual drug therapy can help people with breast cancer that has spread to a few spots (up to 5). The goal was to see if it delays cancer growth and improves quality of life. 87 participants received either standard treat…

This study tested a new combination of two drugs, samuraciclib and elacestrant, in 49 adults with a type of advanced breast cancer (HR+/HER2-). The goal was to find the right dose and see if the combination is safe and can slow cancer growth. Participants had already tried other …

This study tested a new treatment combination (SV-BR-1-GM plus retifanlimab) in 36 people with advanced breast cancer that had stopped responding to standard therapies. The goal was to see if the combination is safe and can shrink tumors. Participants received the treatment every…

This study looked at how well anti-HER2 drugs work in Egyptian women with HER2-positive breast cancer, an aggressive type. Researchers followed 80 patients to see if single or combination therapy improved survival and safety. The goal was to understand real-world effectiveness in…

This study tested whether adding the experimental drug samuraciclib to the standard hormone therapy fulvestrant works better than fulvestrant alone. It involved 60 adults with a common type of advanced breast cancer (HR+/HER2-) that had worsened after prior treatment. The goal wa…

This study tested the drug trastuzumab, given directly into the spinal fluid, for people with HER2-positive breast cancer that spread to the lining of the brain (carcinomatous meningitis). The goal was to find a safe dose and see if it could slow the cancer's growth in the nervou…

This study tested a combination of two drugs, palbociclib and tamoxifen, as the first treatment for people with a certain type of advanced breast cancer (hormone receptor positive, HER2 negative). The goal was to see how long the cancer could be kept from growing. 49 participants…

This study tested an experimental drug called U3-1402 (patritumab deruxtecan) in 121 people with advanced or metastatic breast cancer. The goal was to see if the drug could shrink tumors and how safe it was. Participants received the drug intravenously, and researchers measured r…

This study tested a new drug called taselisib combined with standard anti-HER2 therapies in 68 people with advanced HER2+ breast cancer. The goal was to find the safest dose and see if the combination helps control the cancer. Participants had cancer that had spread or returned, …

This study looked at women with a common type of advanced breast cancer that has spread. They were all taking a hormone pill (aromatase inhibitor) and a targeted drug called palbociclib. The study used a blood test to find when a specific gene mutation (ESR1) appeared, which can …

This study tested a drug called HER3-DXd in 63 adults with breast or lung cancer that had spread to the brain or the lining around the spinal cord. Participants received the drug every three weeks. The goal was to see if it could shrink brain tumors and help people live longer. T…

This study tested a special counseling program called CALM (Managing Cancer and Living Meaningfully) for people with brain cancer. 60 participants were split into two groups: one received CALM plus usual care, the other just usual care. The goal was to see if CALM is practical an…

This study tested whether a 6-month program using an activity tracker and weekly quizzes could improve quality of life and reduce fatigue in women with metastatic breast cancer. 124 women starting chemotherapy were randomly assigned to either receive the activity program plus rec…

This study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib plus fulvestrant for at least one week. Researchers wanted to learn about patients' attitudes toward the dosing schedule and any side effects that affected their ability to stay on…

This study tested a new lab test (RAD51-foci) to see if it can predict whether the drug olaparib will shrink tumors in people with advanced HER2-negative breast cancer who have certain gene mutations (BRCA1, BRCA2, PALB2, RAD51C, or RAD51D). The study involved 65 participants and…

This study looked at 185 people with a common type of advanced breast cancer (HR+/HER2-) who were starting treatment with palbociclib combined with other drugs. Researchers observed how long the treatment kept the cancer from growing and how patients' quality of life changed in e…

This study looked at medical records from about 20,000 women with metastatic breast cancer in France. The goal was to see if other measures, like how long until the cancer gets worse, could replace overall survival (how long patients live) in future trials. By comparing real-worl…

This study looked at 22 adults with advanced HER2-positive or HER2-low breast cancer who were taking the drug trastuzumab deruxtecan (T-DXd). Researchers wanted to see how often patients stopped treatment early or needed dose changes in everyday medical practice. The goal was to …

This study looked at how a continuous glucose monitor (CGM) could help track and manage high blood sugar in 8 adults with metastatic breast cancer starting the drug alpelisib. Participants wore a sensor that measured glucose every minute for at least 3 months. The goal was to und…

This study examined how two specific genes (VEGFR-2 and IL-8) influence how well metastatic breast cancer patients respond to a combination of chemotherapy drugs (paclitaxel and bevacizumab) versus chemotherapy alone. Researchers enrolled 307 patients from ten Italian hospitals. …

This study looked at 60 people with metastatic breast cancer to find out if certain cells in their blood come from the tumor. Researchers took a blood sample before starting treatment and checked for these cells. The goal was to better understand the disease, not to test a new tr…

This study tracked 559 adults in Israel with metastatic breast cancer who were prescribed palbociclib (a targeted therapy) as part of their treatment. Researchers wanted to see how the drug was actually used in real life, including which other medicines were combined with it, how…